Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Element Biosciences in the transaction. Element Biosciences Inc., developer of pioneering technologies to empower science, announced it raised...
Element Biosciences’ $277 Million Series D Financing Round
Xaira Therapeutics’ $1 Billion Funding
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
Archetype AI’s $13 Million Seed Funding Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Archetype AI in the transaction. Archetype AI, a physical AI company, announced its $13 million Seed financing led...
Contineum Therapeutics’ $110 Million IPO
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Contineum Therapeutics in the offering, and Sidley Austin represented the underwriters. Contineum Therapeutics, a clinical stage biopharmaceutical company,...
Natera’s $250 Million Follow-On Offering
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....
Pipeline Therapeutics’ Global License and Development Agreement with Janssen
Gunderson Dettmer represented Pipeline Therapeutics on the deal. Pipeline Therapeutics, a clinical-stage biopharmaceutical company, entered into a global license and development agreement with Janssen Pharmaceutica NV...